Drug Type Antibody drug conjugate (ADC) |
Synonyms- |
Target |
Mechanism MRC2 antagonists(C-type mannose receptor 2 antagonists), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC11H22N4O4 |
InChIKeyAGGWFDNPHKLBBV-YUMQZZPRSA-N |
CAS Registry159858-33-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Sarcoma | Preclinical | GB | 18 Nov 2022 |